Geron Corp (GERN) Misses Q4 EPS by 1c
Get Alerts GERN Hot Sheet
EPS Growth %: -71.4%
Financial Fact:
Interest and other expense: -19K
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Geron Corp (NASDAQ: GERN) reported Q4 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $50 thousand versus the consensus estimate of $50 thousand.
Projected 2021 Financial Guidance:
For fiscal year 2021, the Company expects its operating expense burn to range from $108 to $112 million, which includes costs for the two ongoing Phase 3 clinical trials; producing validation batches of imetelstat at contract manufacturers to enable future production of imetelstat for clinical and commercial purposes; and preparatory activities for NDA and commercial readiness.
As of December 31, 2020, the Company had 55 employees. The Company plans to grow to a total of approximately 80 to 85 employees by year-end 2021, of which the majority will be research and development personnel.
For earnings history and earnings-related data on Geron Corp (GERN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Walgreens Boots Alliance (WBA) tops Q2 expectations, narrows full-year profit forecast
- Achieve Life Sciences (ACHV) Tops Q4 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!